Recent Advances in AI-Assisted Drug Design and Discovery: Current Applications, Challenges, and Future Perspectives-A Review
Keywords:
Artificial intelligence, Drug discovery, Generative AI, Machine learning, Molecular design, Virtual screeningAbstract
Artificial intelligence (AI) has emerged as a transformative technology in pharmaceutical research and drug discovery. Conventional drug discovery is a lengthy and resource-intensive process involving target identification, target validation, hit discovery, lead optimization, preclinical evaluation and clinical development. The increasing availability of chemical, biological, genomic, structural and clinical datasets, together with advances in machine learning and deep learning, has created new opportunities to accelerate several stages of pharmaceutical research. AI-assisted approaches are currently being applied to target identification, virtual screening, quantitative structure–activity relationship modeling, molecular property prediction, de novo molecular design, drug repurposing, toxicity prediction, pharmacokinetic assessment and synthetic-route prediction. Generative artificial intelligence has further expanded these capabilities by enabling the design of novel molecular structures with predefined physicochemical and biological characteristics. Transformer models, graph neural networks, variational autoencoders, generative adversarial networks, reinforcement learning and diffusion models are increasingly being investigated for molecular generation and optimization. Advances in protein-structure prediction, particularly the development of AlphaFold-based technologies, have also provided new opportunities for structure-based drug discovery. AI can assist researchers in prioritizing compounds, identifying potential drug-target interactions and optimizing lead molecules before experimental testing. Despite these advances, significant challenges remain, including data quality, model interpretability, algorithmic bias, chemical validity, reproducibility, generalizability, experimental validation and regulatory acceptance. The increasing use of AI in pharmaceutical research has consequently created a need for appropriate frameworks for model validation, transparency, data governance and regulatory credibility. This review discusses recent advances in AI-assisted drug design and discovery, focusing on current applications, major AI technologies, generative molecular design, structure-based discovery, virtual screening, drug repurposing, ADMET prediction, challenges, regulatory considerations and future perspectives.

.